|
Outcomes of the miltuximab first in human trial and proposed study design for a phase I trial 89Zr/177Lu theranostic trial. |
|
|
|
|
Stock and Other Ownership Interests - Minomic |
Research Funding - Minomic |
Patents, Royalties, Other Intellectual Property - Minomic |
Travel, Accommodations, Expenses - Minomic |
|
|
Research Funding - Minomic |
|
|
|
Consulting or Advisory Role - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Ipsen (Inst); Janssen-Cilag (Inst); Merck Sharp & Dohme (Inst) |
|
|
Consulting or Advisory Role - Minomic |
Research Funding - Minomic (Inst) |
|
|
Employment - Macquarie Medical Imaging |
Research Funding - Minomic (Inst) |
|
|
No Relationships to Disclose |
|
|
Employment - Macquarie Medical Imaging |
Leadership - Macquarie Medical Imaging |
Research Funding - Minomic (Inst) |
|
|
|
Stock and Other Ownership Interests - Minomic |
Research Funding - Minomic |
Patents, Royalties, Other Intellectual Property - Minomic |
|
|
Consulting or Advisory Role - Minomic |
Research Funding - Minomic |
|
|
Consulting or Advisory Role - Minomic |
Research Funding - Minomic |
|
|
No Relationships to Disclose |